The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.
01:51
02:45
02:14
02:14
01:39
02:09
01:20
01:57
01:51
01:36
01:30
03:01
01:39
03:25
02:04
00:58
01:16
00:43
01:35
01:25
01:13
01:05
01:54
01:21
01:50
01:15
01:44
01:31
01:27
01:07
01:13
01:14
00:51
01:15
01:24
01:36
02:12
04:24
01:29
02:14
01:29
02:06
01:21
02:23
01:01
00:58
03:28
02:49
01:37
02:07
00:59
00:39
01:30
00:58
00:54
01:38
01:54
02:27
01:39
01:02
01:46
01:09
01:36
01:34
01:58
02:07
01:35
01:53
01:04
01:08
01:17
02:01
01:37
01:12
02:31